



AB Sustainable Global Thematic Portfolio

Equity Rally Continued

The rally in equity markets continued into 2024 driven by artificial-intelligence (AI) proliferation, a resilient US macroeconomic backdrop and confidence that the easing cycle will start at some point during the year. The disinflation narrative is intact while corporate profits are recovering—an “immaculate disinflation”—for now. Meanwhile, the Fed is proactively shifting policy to protect the US expansion. All of this is consistent with a positive view on the market, reflected in fund flows and rich valuations.

Global markets, as measured by the MSCI* All Country World Index† (ACWI), increased 3.1% in March, bringing 1Q:24 returns to 8.2%, in US-dollar terms.

The Not-So Magnificent 7—Markets Returns Are Diversifying

Despite continued market concentration in 2024 with market-cap weighted indices outperforming their equal weighted counterparts, dynamics are shifting beneath the surface.

The performance of the “Mag 7” has started diverging after trading in unison for most of 2023. Prices of two of the seven stocks that drove last year’s rally have fallen year to date (Apple and Tesla, neither of which is owned in our Portfolio).

In addition, while the breadth of the rally is still uninspiring, it has started to improve with a rising share of stocks trading above their 200-day moving average. This dynamic is also reflected in the performance of sectors. After having underperformed in prior months, energy and materials are now the top two performing sectors over the past month, while consumer discretionary and technology—home to Tesla and NVIDIA—have moved down in rank to the very bottom of the list.

According to Goldman Sachs (unheld), other concentrated markets in the past 100 years often ended in “catch-up” rallies as the market broadened. This suggests a further broadening in the coming months could lead to more gains overall.

Expect Broadening, but Still Modest Economic Growth

In aggregate, companies delivered another earnings beat in 4Q:23 and the consensus 2024 GDP forecast has risen, a reflection of the better-than-feared economic backdrop and optimism over a soft landing.

The narrowness of recent profit growth presents a potential cautionary note for markets. Excluding the “Mag 6” companies (the Mag 7 less Tesla, [NVIDIA, Meta Platforms (unheld), Amazon (unheld), Microsoft, Alphabet Inc. (unheld) and Apple], which is struggling with more idiosyncratic issues), S&P 500‡ corporate earnings declined year over year in each of the final three quarters of 2023, or down 9% on a cumulative basis. In contrast, cumulative earnings rose 120% for the Mag 6.

We believe earnings growth can broaden in 2024, which bodes well for market returns beyond the largest technology stocks. In fact, consensus estimates are in for a catch up in terms of earnings growth for the rest of the market for the back end of 2024. Finally, we would note that despite recent positive GDP revisions, the economic outlook for the next several years is still fairly

*MSCI indices measure the performance of different stock types in geographic areas. They track the performance of the stocks included in the index and are used as the base for exchange-traded funds.

†An investor cannot invest directly in an index, and index results are not indicative of the performance for any specific investment, including an AB fund. Indices do not include sales charges or operating expenses associated with an investment in a mutual fund, which would reduce total returns.

‡The S&P 500 is a stock market index that measures the stock performance of 500 large companies listed on stock exchanges in the United States.

anemic. The consensus currently expects real GDP growth of just 1.5% for 2024 and 2025 for the Group of Eight countries. That's a constructive backdrop for stronger, more resilient, less macro-dependent themes like those we target in our strategies.

Post-COVID-19 Normalization—A Tailwind to Our Portfolios

Global supply chains were materially disrupted during COVID-19, leading to boom/bust cycles within certain industries including healthcare tools and instruments suppliers, which negatively impacted our Portfolio. However, with supply chain pressures moderating and healthcare utilization generally improving, many healthcare companies are pointing to stronger growth this year. Bioprocessing, for example, is showing clear signs of bottoming/rebounding, which bodes well for our Medical Innovation theme.

More broadly, aggregate inventory levels have just returned to normal and a restocking wave could spur growth in manufacturing in the quarters ahead.

Final Thoughts

Over many years of managing investors' money, we have seen clients lose patience and chase returns via recent winners. History shows investors get penalized when purchasing an asset expensively—even when fundamentals are positive. We believe many of today's largest technology firms fit this profile, while opportunities exist to find companies with similar growth rates at more attractive prices elsewhere.

Portfolio Performance

Class A shares of the AB Sustainable Global Thematic Portfolio increased in absolute terms but underperformed their Benchmark, the MSCI ACWI, in March and for 1Q:24, net of fees. During the quarter, stock selection detracted from overall returns, while sector selection contributed. Stock selection within technology and financials detracted the most, while selection in industrials and an overweight to technology contributed.

Infineon Technology, from our Climate theme, engages in the provision of power and sensing solutions, as well as technologies for the electrification of the automotive industry. Shares detracted on concern that a slowing macroeconomic environment will have a negative impact on semiconductor end-users, especially in the automotive industry. We believe increasing demand for electric vehicles, renewables and auto safety will provide opportunities for growth over the long term.

Adobe, from our Empowerment theme, detracted after reporting a strong first quarter but providing a lighter-than-expected outlook for the company's second quarter, where expectations for further uplift from monetization of Adobe's newer generative AI products released last year was higher. The company highlighted a number of positives in the quarter, including operating margin expansion even in the face of continued new product releases, strength from its research and development organization, and a four-year \$US25 billion share buyback program. We expect the second half of the year to demonstrate strength, and we remain confident in Adobe's growth trajectory, supported by several recent and upcoming product launches and the prospects for AI monetization.

Calix, a provider of internet access equipment for network buildouts in the US, from our Empowerment theme, detracted as customers shifted planning resources to applying for a massive funding program from the US government, the Broadband Equity, Access, and Deployment (BEAD) Program. While deployments have slowed in 2024, it creates an even bigger potential setup for growth in 2025, when disbursements from BEAD flow in earnest and Calix's customers race to deploy. We think investors will get excited about the company as we get closer to this reality.

Flex, an outsourced manufacturer of products including communication devices and autonomous driving systems for electric cars, from our Climate theme, contributed after posting strong performance during the period. The company is seen as a beneficiary of AI-related data center spend as it produces servers and full rack systems for customers. Additionally, operating margins have been stronger than expected, which supports earnings in the face of macroeconomic-related headwinds in the consumer and industrial segments.

ASML, a provider of advanced lithography technology for the semiconductor industry, also from our Empowerment theme, contributed after it beat earnings expectations amid record bookings; it also had some positive commentary surrounding installed base and margin tailwind. The massive order figure suggests increasing confidence for growth reaccelerating in 2025.

Taiwan Semiconductor Manufacturing, the world's largest chipmaker, from our Climate theme, contributed following growing need for semiconductors driven by AI demand.

Thematic Check—Steady Progress

Amid all the noise, our themes continue to move forward as broad shifts in the global economy run their course. Global challenges such as access to healthcare and infrastructure needs are not solved overnight. Although having less exposure to the mega-cap technology cohort has not helped, our core thematic exposures continue to offer robust growth potential.

We believe a portfolio with high-quality companies on the right side of change, trading at reasonable valuations, provides a strong combination for the current market environment. Resilient fundamentals and narrow leadership in the market has created a powerful setup for a group of companies that fit this profile.

Within our Information, Communication and Technologies theme, the latest earnings results from a number of leaders like NVIDIA, AMD (unheld) and the cloud providers demonstrates that society's move toward intelligent digital economies is leading to increased demand for bigger networks, more powerful and energy efficient data centers and new consumption models. We continue to expect the key AI enablers (the companies that facilitate the training and running of AI models in an energy efficient way), along with the AI adopters (those that successfully integrate AI in their applications) will enjoy strong tailwinds near-term.

We are also excited about infrastructure opportunities in the quarters and years ahead. Many roads, bridges, sewer systems and buildings in this country are aging and requires updating. The need for significant Federal funding will be partially met with the bi-partisan Infrastructure Investment and Jobs Act, the CHIPS Act and the Inflation Reduction Act that together should lead to the deployment of over US\$1 trillion in new funding over the next decade. The goal of this legislation is to return the US to a position of industrial and technological leadership in the world. This, in our view, will provide a durable investment backdrop for many of our Portfolio companies. Some of our areas of investment focus include water infrastructure and equipment, grid resilience, and the renewable energy ecosystem.

In our Health theme, the underlying growth in medical innovation remains robust. In 2023, we saw the second highest number of new novel drug approvals by the FDA (55) in the past 10+ years. This growth hasn't translated into earnings for the suppliers in this ecosystem because of excess inventory, but it is finally being worked through. The year 2024 should see a recovery in earnings as a result, despite ongoing headwinds in China. The market enthusiasm around GLP-1 weight loss drugs continues to be high, although we've seen some evidence that the cost of these treatments born by payors will limit adoption below what bullish estimates assume. Our preferred stance continues to be via exposure to the enablers that develop instruments for drug discovery, clinical trial management and packaging, rather than through the end product vendor. This allows us to participate in the underlying market growth without assuming the concentrated risk of owning the GLP-1 providers themselves.

Our thematic research effort remains robust and we are excited to dive deeper into several topics this year including China's domestic semiconductor supply efforts, AI and energy implications, and the effect of climate disasters on the availability of insurance. We look forward to sharing our conclusions with you in the quarters ahead. Our Portfolios continue to harness powerful thematic drivers through companies that in our view are best positioned to capitalize on these opportunities. This approach has delivered strong results for our clients over time and we're highly confident in its ability to do so in the future.

As always, thank you for your continued support.

Dan Roarty

Please refer to the following legal disclosures.

The value of an investment can go down as well as up, and investors may not get back the full amount they invested. Capital is at risk. Past performance does not guarantee future results.

Some of the principal risks of investing include Market Risk, Currency Risk, Derivatives Risk, OTC Derivatives Counterparty Risk, Allocation Risk, Overseas Assets Risk, Systemic Risk, Turnover Risk, Illiquid Securities Risk, Leverage Risk, Equities Risk, Concentrated (Focused Portfolio) Risk, Smaller-Capitalization Companies Risk and Long/Short Strategies Risk.

A full explanation of the risks is provided in the Portfolio's Prospectus.

Important Information: The views expressed here may change at any time after the date of this publication. This document is for informational purposes only and does not constitute investment advice. AllianceBernstein L.P. does not provide tax, legal or accounting advice. It does not take an investor's personal investment objectives or financial situation into account; investors should discuss their individual circumstances with appropriate professionals before making any decisions. This information should not be construed as sales or marketing material, or an offer or solicitation for the purchase or sale of any financial instrument, product or service sponsored by AllianceBernstein or its affiliates. References to specific securities are provided solely in the context of the analysis presented and are not to be considered recommendations by AllianceBernstein. AllianceBernstein and its affiliates may have positions in, and may effect transactions in, the markets, industry sectors and companies described herein. The views expressed herein do not constitute research, investment advice or trade recommendations and do not necessarily represent the views of all AB portfolio-management teams. Holdings are subject to change and may no longer be held in the Portfolio. This document is not an advertisement and is not intended for public use or additional distribution. The sale of AB funds may be restricted or subject to adverse tax consequences in certain jurisdictions. This information is directed solely at persons in jurisdictions where the funds and relevant share class are registered or who may otherwise lawfully receive it.

The sale of AB funds may be restricted or subject to adverse tax consequences in certain jurisdictions. This information is directed solely at persons in jurisdictions where the funds and relevant share class are registered or at those who may otherwise lawfully receive it. Before investing, investors should review the Fund's full Prospectus, which includes Sustainability-Related Disclosures, together with the Fund's KIID or KID and the most recent financial statements. Copies of these documents, including the latest annual report and, if issued thereafter, the latest semiannual report, may be obtained free of charge from AllianceBernstein (Luxembourg) S.à r.l. by visiting www.alliancebernstein.com or www.eifs.lu/alliancebernstein.com, or in printed form by contacting the local distributor in the jurisdictions in which the funds are authorised for distribution.

The AB Portfolio is a sub-fund of AB SICAV I, an open-ended investment company with variable capital (société d'investissement à capital variable) incorporated under the laws of the Grand Duchy of Luxembourg.

The Portfolio uses the Benchmark shown for comparison purposes only. The Portfolio is actively managed and the Investment Manager is not constrained by its Benchmark when implementing the Portfolio's investment strategy. Investors should refer to the latest Fact Sheet published on www.alliancebernstein.com for latest performance data for the Portfolio.

Note to All Readers: The information contained herein reflects the views of AllianceBernstein L.P. or its affiliates and sources it believes are reliable as of the date of this publication. AllianceBernstein L.P. makes no representations or warranties concerning the accuracy of any data. There is no guarantee that any projection, forecast or opinion in this material will be realized.

Note to Readers in the United Kingdom and Europe: For Investment Professional use only. Not for inspection by, distribution or quotation to, the general public.

This document has been approved by AllianceBernstein Limited, an affiliate of AllianceBernstein L.P.

Note to Readers in the United Kingdom: Issued by AllianceBernstein Limited, 60 London Wall, London EC2M 5SJ, registered in England, No. 2551144. AllianceBernstein Limited is authorised and regulated in the UK by the Financial Conduct Authority (FCA). **Note to Readers in Europe:** This information is issued by AllianceBernstein (Luxembourg) S.à r.l. Société à responsabilité limitée, R.C.S. Luxembourg B 34 305, 2-4, rue Eugène Ruppert, L-2453 Luxembourg. Authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF). **Note to Readers in Switzerland:** This information is directed at Qualified Investors only. It does not constitute an offer of the Fund in Switzerland. Issued by AllianceBernstein Schweiz AG, Zürich, a company registered in Switzerland under company number CHE-306.220.501. Swiss Representative and Paying Agent of the Fund: BNP Paribas, Paris, Succursale de Zurich, Selnastrasse 16, 8002 Zürich, Switzerland. The Prospectus, the KIDs, the Articles or management regulations, and the annual and semi-annual reports of the concerned Fund may be obtained free of charge from the Swiss Representative or by visiting www.alliancebernstein.com. AllianceBernstein Schweiz AG is a financial service provider within the meaning of the Financial Services Act (FinSA) and is not subject to any prudential supervision in Switzerland. Further information on the company, its services and products, in accordance with Art. 8 FinSA can be found on the Important Disclosures page at www.alliancebernstein.com. **Note to Readers in Canada:** AllianceBernstein provides its investment-management services in Canada through its affiliates Sanford C. Bernstein & Co. LLC and AllianceBernstein Canada, Inc. It should not be construed as advice as to the investing in or the buying or selling of securities, or as an activity in furtherance of a trade in securities. **Note to Readers in Australia and New Zealand:** This document has been issued by AllianceBernstein Australia Limited (ABN 53 095 022 718 and AFSL 230698). Information in this document is intended only for persons who qualify as "wholesale clients," as defined in the Corporations Act 2001 (Cth of Australia) or the Financial Advisers Act 2008 (New Zealand), and should not be construed as advice. **Note to Readers in Singapore: For financial representative use only. Not for inspection by, distribution or quotation to, the general public.** AllianceBernstein (Luxembourg) S.à r.l. is the management company of the Portfolio and has appointed AllianceBernstein (Singapore) Ltd. (Company Registration No. 199703364C) as its agent for service of process and as its Singapore representative. AllianceBernstein (Singapore) Ltd. is regulated by the Monetary Authority of Singapore. This advertisement has not been reviewed by the Monetary Authority of Singapore. **Note to Readers in Hong Kong: For financial representative or professional investor use only. Not for inspection by, distribution or quotation to, the general public.** The issuer of this document is AllianceBernstein Hong Kong Limited (聯博香港有限公司). This document has not been reviewed by the Securities and Futures Commission. **Additional Disclosure for Readers in Singapore and Hong Kong:** The Portfolio is part of AB SICAV I (referred to as "AB"). AB is an open-ended investment company with variable capital (société d'investissement à capital variable) incorporated under the laws of the Grand Duchy of Luxembourg. Prior to 5 February 2016, AB's legal name was ACMBernstein SICAV; its trading name was AllianceBernstein. Investment in the Fund entails certain risks. Investment returns and principal value of the Fund will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. The Portfolio is meant as a vehicle for diversification and does not represent a complete investment program. Returns denominated in a currency other than the base currency of the Portfolio may increase or decrease as a result of foreign exchange currency fluctuations. Financial derivative instruments may be used for investment purposes and/or for hedging and/or EPM purposes, which may involve additional risks different from, and, in certain cases, greater than, the risk presented by more traditional investments. These and other risks are described in the Portfolio's Prospectus. Prospective investors should read the Prospectus and Product Highlight Sheets/Product Key Facts, including risk factors, carefully and discuss risk and the Portfolio's fees and charges with their financial adviser to determine if the investment is appropriate for them. These documents may be obtained free of charge from www.alliancebernstein.com / www.abfunds.com or by contacting the local distributor in the jurisdictions in which the Portfolios are authorized for distribution. The performance discussed in this commentary is net of fees and expenses, but does not account for the potential sales charges that may apply to certain share classes of the Portfolio.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed or produced by MSCI.

The [A/B] logo is a registered service mark of AllianceBernstein and AllianceBernstein® is a registered service mark used by permission of the owner, AllianceBernstein L.P. © 2024 AllianceBernstein L.P.

Doc ID: 27, LF-524115-2024-04-08, ICN20240529

Quarterly Commentary